Siegel WatkinsE. How the PILL Became a LIFESTYLE DRUG: The Pharmaceutical Industry and Birth Control in the United States Since 1960. American Journal of Public Health2012 Aug; 102(8): 1462–1472.
2.
VarolNCosta-FontJMcGuireA. Does Adoption of Pharmaceutical Innovation Respond to Changes in the Regulatory Environment?Applied Economic Perspectives & Policy2012 Sep; 34(3): 531–553.
3.
WilkieDCHJohnsonLWWhiteL. Strategies used to defend pharmaceutical brands from generics. European Journal of Marketing2012 Oct; 46(9): 1195–1214.
4.
FischerKE. A systematic review of coverage decision-making on health technologies: Evidence from the real world. Health Policy2012 Oct; 107(2/3): 218–230.
5.
RobinsonJC. Providers' Payment And Delivery System Reforms Hold Both Threats And Opportunities For The Drug And Device Industries. Health Affairs2012 Sep; 31(9): 2059–2067.
6.
Costa-FontJMcGuireASerra-SastreV. The ‘Weisbrod Quadrilemma’ Revisited: Insurance Incentives on New Health Technologies. Geneva Papers on Risk & Insurance - Issues & Practice2012 Oct; 37(4): 678–695.
